# EDGAR Filing Document

**Accession Number:** 0001131399
**File Stem:** 0001999371-25-019650
**Filing Date:** 2025-12
**Character Count:** 12680
**Document Hash:** 39d6eb467ac58a88ebdc66795fc4813d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001999371-25-019650.hdr.sgml**: 20251205

**ACCESSION NUMBER**: 0001999371-25-019650

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251205

**DATE AS OF CHANGE**: 20251205

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CureVac N.V.
- **CENTRAL INDEX KEY:** 0001809122
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91630
- **FILM NUMBER:** 251553248

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** FRIEDRICH-MIESCHER-STRASSE 15
- **CITY:** TUBINGEN
- **NON US STATE TERRITORY:** BADEN-WURTTEMBERG
- **PROVINCE COUNTRY:** 2M
- **ZIP:** 72076
- **BUSINESS PHONE:** 49 7071 9883 0

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** FRIEDRICH-MIESCHER-STRASSE 15
- **CITY:** TUBINGEN
- **NON US STATE TERRITORY:** BADEN-WURTTEMBERG
- **PROVINCE COUNTRY:** 2M
- **ZIP:** 72076

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CureVac B.V.
- **DATE OF NAME CHANGE:** 20200410
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GSK plc
- **CENTRAL INDEX KEY:** 0001131399
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 79 NEW OXFORD STREET
- **CITY:** LONDON
- **PROVINCE COUNTRY:** X0
- **BUSINESS PHONE:** 44 20 8047 5000

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 79 NEW OXFORD STREET
- **CITY:** LONDON
- **PROVINCE COUNTRY:** X0

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GSK PLC
- **DATE OF NAME CHANGE:** 20220516

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GLAXOSMITHKLINE PLC
- **DATE OF NAME CHANGE:** 20010105

## Ex-99

**Exhibit**

**Schedule A – Item 2(c)**

**GSK**

**Directors and Executive Officers**

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**Name** | &nbsp;&nbsp;**Business Address** | &nbsp;&nbsp;**Principal Occupation or Employment** | &nbsp;&nbsp;**Citizenship** |
| &nbsp;&nbsp;***Board of Directors*** | &nbsp;&nbsp;***Board of Directors*** | &nbsp;&nbsp;***Board of Directors*** | &nbsp;&nbsp;***Board of Directors*** |
| &nbsp;&nbsp;Sir Jonathan Symonds CBE | &nbsp;&nbsp;79 New Oxford Street, London, WC1A 1DG, United Kingdom | &nbsp;&nbsp;Chair and Company Director | &nbsp;&nbsp;British |
| &nbsp;&nbsp;Emma Walmsley | &nbsp;&nbsp;79 New Oxford Street, London, WC1A 1DG, United Kingdom | &nbsp;&nbsp;Executive Director | &nbsp;&nbsp;British |
| &nbsp;&nbsp;Julie Brown | &nbsp;&nbsp;79 New Oxford Street, London, WC1A 1DG, United Kingdom | &nbsp;&nbsp;Executive Director | &nbsp;&nbsp;British |
| &nbsp;&nbsp;Elizabeth McKee Anderson | &nbsp;&nbsp;79 New Oxford Street, London, WC1A 1DG, United Kingdom | &nbsp;&nbsp;Company Director | &nbsp;&nbsp;US |
| &nbsp;&nbsp;Charles Bancroft | &nbsp;&nbsp;79 New Oxford Street, London, WC1A 1DG, United Kingdom | &nbsp;&nbsp;Company Director | &nbsp;&nbsp;US |
| &nbsp;&nbsp;Dr. Hal Barron | &nbsp;&nbsp;79 New Oxford Street, London, WC1A 1DG, United Kingdom | &nbsp;&nbsp;Company Director | &nbsp;&nbsp;US |
| &nbsp;&nbsp;Dr. Anne Beal | &nbsp;&nbsp;79 New Oxford Street, London, WC1A 1DG, United Kingdom | &nbsp;&nbsp;Company Director | &nbsp;&nbsp;US |
| &nbsp;&nbsp;Wendy Becker | &nbsp;&nbsp;79 New Oxford Street, London, WC1A 1DG, United Kingdom | &nbsp;&nbsp;Company Director | &nbsp;&nbsp;British & US & Italian |
| &nbsp;&nbsp;Dr. Harry (Hal) Dietz | &nbsp;&nbsp;79 New Oxford Street, London, WC1A 1DG, United Kingdom | &nbsp;&nbsp;Company Director | &nbsp;&nbsp;US |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**Name** | &nbsp;&nbsp;**Business Address** | &nbsp;&nbsp;**Principal Occupation or Employment** | &nbsp;&nbsp;**Citizenship** |
| &nbsp;&nbsp;Dr. Gavin Screaton | &nbsp;&nbsp;79 New Oxford Street, London, WC1A 1DG, United Kingdom | &nbsp;&nbsp;Company Director | &nbsp;&nbsp;British |
| &nbsp;&nbsp;Dr. Jeannie Tsun-Huei Lee | &nbsp;&nbsp;79 New Oxford Street, London, WC1A 1DG, United Kingdom | &nbsp;&nbsp;Company Director | &nbsp;&nbsp;US |
| &nbsp;&nbsp;Dr. Vishal Sikka | &nbsp;&nbsp;79 New Oxford Street, London, WC1A 1DG, United Kingdom | &nbsp;&nbsp;Company Director | &nbsp;&nbsp;US |
| &nbsp;&nbsp;**GSK Leadership Team** | &nbsp;&nbsp;**GSK Leadership Team** | &nbsp;&nbsp;**GSK Leadership Team** | &nbsp;&nbsp;**GSK Leadership Team** |
| &nbsp;&nbsp;Emma Walmsley | &nbsp;&nbsp;79 New Oxford Street, London, WC1A 1DG, United Kingdom | &nbsp;&nbsp;Chief Executive Officer | &nbsp;&nbsp;British |
| &nbsp;&nbsp;Julie Brown | &nbsp;&nbsp;79 New Oxford Street, London, WC1A 1DG, United Kingdom | &nbsp;&nbsp;Chief Financial Officer | &nbsp;&nbsp;British |
| &nbsp;&nbsp;Diana Conrad | &nbsp;&nbsp;79 New Oxford Street, London, WC1A 1DG, United Kingdom | &nbsp;&nbsp;Chief People Officer | &nbsp;&nbsp;Canadian |
| &nbsp;&nbsp;James Ford | &nbsp;&nbsp;79 New Oxford Street, London, WC1A 1DG, United Kingdom | &nbsp;&nbsp;SVP and Group General Counsel, Legal and Compliance | &nbsp;&nbsp;British & US |
| &nbsp;&nbsp;Sally Jackson | &nbsp;&nbsp;79 New Oxford Street, London, WC1A 1DG, United Kingdom | &nbsp;&nbsp;SVP, Global Communications and CEO Office | &nbsp;&nbsp;British |
| &nbsp;&nbsp;Luke Miels | &nbsp;&nbsp;79 New Oxford Street, London, WC1A 1DG, United Kingdom | &nbsp;&nbsp;Chief Commercial Officer and CEO Designate | &nbsp;&nbsp;Australian |
| &nbsp;&nbsp;Shobana Ramakrishnan | &nbsp;&nbsp;79 New Oxford Street, London, WC1A 1DG, United Kingdom | &nbsp;&nbsp;Chief Digital & Technology Officer | &nbsp;&nbsp;US |
| &nbsp;&nbsp;David Redfern | &nbsp;&nbsp;79 New Oxford Street, London, WC1A 1DG, United Kingdom | &nbsp;&nbsp;President, Corporate Development | &nbsp;&nbsp;British |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**Name** | &nbsp;&nbsp;**Business Address** | &nbsp;&nbsp;**Principal Occupation or Employment** | &nbsp;&nbsp;**Citizenship** |
| &nbsp;&nbsp;Regis Simard | &nbsp;&nbsp;79 New Oxford Street, London, WC1A 1DG, United Kingdom | &nbsp;&nbsp;President, Global Supply Chain | &nbsp;&nbsp;French & British |
| &nbsp;&nbsp;Philip Thomson | &nbsp;&nbsp;79 New Oxford Street, London, WC1A 1DG, United Kingdom | &nbsp;&nbsp;President, Global Affairs | &nbsp;&nbsp;British |
| &nbsp;&nbsp;Deborah Waterhouse | &nbsp;&nbsp;79 New Oxford Street, London, WC1A 1DG, United Kingdom | &nbsp;&nbsp;CEO, ViiV Healthcare and President Global Health, GSK | &nbsp;&nbsp;British |
| &nbsp;&nbsp;Dr. Tony Wood | &nbsp;&nbsp;79 New Oxford Street, London, WC1A 1DG, United Kingdom | &nbsp;&nbsp;Chief Scientific Officer | &nbsp;&nbsp;British |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**CureVac N.V.**

*(Name of Issuer)*

**Common Shares, par value (euro) 0.12 per share**

*(Title of Class of Securities)*

**N2451R105**

*(CUSIP Number)*

**Victoria A. Whyte**<br>79 New Oxford Street<br>London X0 WC1A 1DG<br>44 020 8047 5000

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**12/03/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **N2451R105** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**GSK plc** | Name of reporting person<br>**GSK plc** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X0** | Citizenship or place of organization<br>**X0** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**0.00** | Aggregate amount beneficially owned by each reporting person<br>**0.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.00%** | Percent of class represented by amount in Row (11)<br>**0.00%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**HC** | Type of Reporting Person (See Instructions)<br>**HC** | |

---

**Comment for Reporting Person:** (1) Common Shares previously reported were held directly by Glaxo Group Limited ("GGL"), an indirect wholly-owned subsidiary of GSK plc.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Shares, par value (euro) 0.12 per share

**(b) Name of Issuer:**
CureVac N.V.

**(c) Address of Issuer's Principal Executive Offices:**
Friedrich-Miescher-Strasse 15, Tubingen, 2M, 72076

This Amendment No. 1 to Schedule 13D (this "Amendment No. 1") amends and supplements the statement on Schedule 13D originally filed by GSK plc ("GSK") with the Securities and Exchange Commission on August 13, 2025 (the "Schedule 13D") with respect to the common shares, (euro) 0.12 par value per share (the "Common Shares"), of CureVac N.V., a public limited liability company (naamloze vennootschap) organized under the laws of The Netherlands (the "Issuer"), whose principal executive offices are located at Friedrich-Miescher-Strasse 15, 72076 Tubingen, Germany. Capitalized terms used herein and not otherwise defined in this Amendment No. 1 have the meanings set forth in the Schedule 13D. This Amendment No. 1 is the final amendment to the Schedule 13D and constitutes an "exit filing" for GSK.

**Item 4. Purpose of Transaction**

Item 4 of the Schedule 13D is hereby amended by adding the following:

Pursuant to the terms of the Tender and Support Agreement, GGL tendered all Common Shares held by it in the Exchange Offer. The Exchange Offer expired as scheduled at 9:00 a.m. Eastern Time on December 3, 2025. The Common Shares held by GGL were accepted for exchange on December 3, 2025. As a result, GSK, through its wholly-owned indirect subsidiary GGL, no longer beneficially owns, or otherwise holds, any securities of the Issuer.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Item 5(a) of the Schedule 13D is hereby amended and restated as set forth below:

The responses of GSK to Rows (7) through (13) of the cover pages of this Amendment No. 1 are hereby incorporated by reference in this Item 5(a).

**(b)**
Item 5(b) of the Schedule 13D is hereby amended and restated as set forth below:

Except as disclosed in this Amendment No.1, neither GSK nor, to the best of its knowledge, any of the persons listed in Schedule A to the Schedule 13D, (i) beneficially owned, or had the right to acquire, any Common Shares, or (ii) had the power to vote or to direct the vote, or to dispose or direct the disposition, of any of the Common Shares.

**(c)**
Item 5(c) of the Schedule 13D is hereby amended and restated as set forth below:

Except as disclosed in Item 4, neither GSK nor, to the best of its knowledge, any of the persons listed in Schedule A of the Schedule 13D, has effected any transaction in the Common Shares during the past sixty (60) days.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** GSK plc

**Signature:** /s/ Victoria A. Whyte

**Name/Title:** Victoria A. Whyte, Authorized Signatory

**Date:** 12/05/2025